Hereditary adult-onset ataxias are a diverse group of neurodegenerative disorders that impair movement and coordination. Their causes often lie in hidden stretches of DNA - short tandem repeat expansions that disrupt neural pathways. Until now, diagnosis has relied on PCR-based testing, a method that is laborious, sequential, and often blind to rarer forms of the disease. The result: delayed diagnoses, missed conditions, and incomplete understanding of how these disorders manifest.
A recent German study has changed that landscape. By using clinical nanopore Cas9-targeted sequencing (Clin-CATS), a form of long-read sequencing (LRS), researchers analyzed more than 500 patients with adult-onset ataxia, offering the most comprehensive look yet at repeat-associated ataxias in a clinical cohort.
The Study
In this large diagnostic cohort of 513 patients, researchers applied long-read sequencing enriched with Cas9 targeting to analyze all known repeat-associated ataxias, with the exception of SCA4 where the causative gene remains under debate. The goal was to capture both common and rare genetic expansions, to measure carrier frequencies of recessive disorders, and to test whether this new method could outperform the older PCR-based approaches.
The analysis confirmed repeat-associated ataxias in one-third of patients. While the most common diagnoses were RFC1 spectrum disorder and SCA27B, rarer conditions such as SCA10, SCA36, and SCA37 were also detected, demonstrating the wider reach of long-read sequencing. In addition, potentially pathogenic expansions in FGF14 were found in nearly five percent of patients, opening new diagnostic pathways. Another striking finding was the presence of dual diagnoses in over six percent of patients, revealing a level of genetic complexity often invisible to traditional tests.
Carrier frequencies were also clarified. RFC1 carriers were present at a rate of more than seven percent, a surprisingly high number, while reclassification of certain FXN expansions lowered the estimated carrier frequency of Friedreich's ataxia to less than one percent. The study further identified novel repeat configurations, illustrating how PCR methods can misclassify results and lead to false conclusions.
Why It Matters
This work demonstrates that long-read sequencing delivers not only higher accuracy but also a more comprehensive view of genetic architecture. Unlike PCR testing, which hunts for one suspect repeat at a time, long-read sequencing captures the full landscape of repeat expansions in a single analysis. This is crucial for patients whose symptoms overlap across multiple subtypes of ataxia. The findings also highlight how genetic variation within the same repeat locus can shape very different clinical outcomes, challenging existing genotype-phenotype correlations.
A New Standard for Clinical Genetics
The authors recommend that long-read sequencing replace PCR and Southern blot as the new diagnostic standard for hereditary ataxias. With its precision, inclusivity of rare expansions, and ability to reduce both false positives and negatives, it represents a decisive step toward more reliable and efficient diagnosis. It also lays the groundwork for deeper research into how repeat expansions cause disease and why symptoms vary so widely.
Reflection
Ataxias remind us how patterns in the genome shape the body's ability to move with balance and grace. For decades, medicine attempted to decode these patterns using fragmentary tools. Long-read sequencing finally reveals the full architecture of genetic repetition - not only the size of an expansion, but its hidden structures, dualities, and variations. In this way, the study is about more than neurology: it is about learning to read the language of repetition itself. Just as repeating signals in the brain govern coordination, repeating codes in DNA govern vulnerability. By making these codes visible, long-read sequencing transforms blind repetition into knowledge, and knowledge into better care.
Toward Precision Medicine
With more than one-third of patients receiving confirmed diagnoses through this new approach, the study makes a powerful case: the era of piecemeal PCR testing is ending. The future of neurogenetic diagnosis lies in technologies that read patterns in their entirety. By embracing long-read sequencing, medicine moves closer to precision care - where hidden repetitions are no longer sources of confusion, but guides toward healing.
